MCID: CRC006
MIFTS: 59

Carcinoid Syndrome

Categories: Rare diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Carcinoid Syndrome

MalaCards integrated aliases for Carcinoid Syndrome:

Name: Carcinoid Syndrome 49
Carcinoid Tumor 49 28 69
Carcinoid Tumor No Icd-O Subtype 69
Malignant Carcinoid Syndrome 69
Carcinoid Tumor Syndrome 49
Carcinoid Tumors 40

Classifications:



Summaries for Carcinoid Syndrome

NIH Rare Diseases : 49 Carcinoid syndrome refers to a group of symptoms that are associated with carcinoid tumors (rare, slow-growing tumors that occur most frequently in the gastroinestinal tract or lungs). Affected people may experience skin flushing, abdominal pain, diarrhea, difficulty breathing, rapid heart rate, low blood pressure, skin lesions on the face (telangiectasias), and wheezing. In later stages, carcinoid syndrome may damage the heart valves, resulting in symptoms of congestive heart failure. The condition occurs when the carcinoid tumor secretes serotonin or other chemicals into the bloodstream. Only 10% of people with carcinoid tumors develop carcinoid syndrome; most have advanced stage carcinoid tumors that have spread to the liver. Treatment generally involves addressing the underlying carcinoid tumor and medications to alleviate symptoms. Last updated: 9/25/2015

MalaCards based summary : Carcinoid Syndrome, also known as carcinoid tumor, is related to carcinoid tumors, intestinal and multiple endocrine neoplasia, and has symptoms including right ventricular failure, palpitations and nausea and vomiting. An important gene associated with Carcinoid Syndrome is CHGA (Chromogranin A), and among its related pathways/superpathways are Neuroscience and HIF-1 signaling pathway. The drugs Miconazole and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, liver and heart, and related phenotypes are growth/size/body region and homeostasis/metabolism

MedlinePlus : 40 Carcinoid tumors are rare, slow-growing cancers. They usually start in the lining of the digestive tract or in the lungs. They grow slowly and don't produce symptoms in the early stages. As a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. In later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. The syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. Surgery is the main treatment for carcinoid tumors. If they haven't spread to other parts of the body, surgery can cure the cancer.

Related Diseases for Carcinoid Syndrome

Diseases related to Carcinoid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 245)
# Related Disease Score Top Affiliating Genes
1 carcinoid tumors, intestinal 32.1 CHGA ENO2 MEN1 SST SYP
2 multiple endocrine neoplasia 30.0 CALCA CHGA MEN1
3 zollinger-ellison syndrome 29.9 CHGA MEN1 NTS SST
4 serotonin syndrome 29.8 CHGA GHRH HTR3A IFNA2 MEN1 PYY
5 vipoma 29.6 CALCA CHGA NTS SST
6 multiple endocrine neoplasia, type i 29.6 CHGA MEN1 SST SYP
7 acromegaly 29.3 GHRH IGF1 MEN1 SST
8 gastrointestinal neuroendocrine tumor 29.3 CHGA SYP VEGFA
9 somatostatinoma 29.2 CALCA CHGA ENO2 SST
10 neuroendocrine tumor 29.1 CALCA CHGA ENO2 MEN1 NTS SST
11 pheochromocytoma 28.4 CALCA CHGA ENO2 MEN1 NPY SST
12 neurofibromatosis-pheochromocytoma-duodenal carcinoid syndrome 12.0
13 ureter small cell carcinoma 10.6 CHGA SYP
14 gastrointestinal neuroendocrine benign tumor 10.6 CHGA SST
15 gastric neuroendocrine neoplasm 10.6 CHGA SST
16 esophageal neuroendocrine tumor 10.6 CHGA SYP
17 ovarian large-cell neuroendocrine carcinoma 10.6 CHGA SYP
18 acinar cell cystadenocarcinoma 10.6 CHGA SYP
19 peritoneal serous adenocarcinoma 10.6 CHGA SYP
20 malignant glandular tumor of peripheral nerve sheath 10.6 SST SYP
21 wdha syndrome 10.6 CALCA SST
22 cellular ependymoma 10.6 CHGA SYP
23 primary hepatic neuroendocrine carcinoma 10.6 CHGA SYP
24 chordoid meningioma 10.6 CHGA SYP
25 pancreatic endocrine carcinoma 10.5 SST SYP
26 pituitary carcinoma 10.5 CHGA SST
27 conventional angiosarcoma 10.5 CHGA SYP
28 hyperinsulinemic hypoglycemia, familial, 2 10.5 CHGA SST
29 prolactin producing pituitary tumor 10.5 CALCA SST
30 leprosy 2 10.5 CALCA NPY
31 acidophil adenoma 10.5 IGF1 SST
32 pulmonary sclerosing hemangioma 10.5 CHGA SYP
33 pituitary infarct 10.5 IGF1 SST
34 reflex sympathetic dystrophy 10.5 CALCA NPY
35 adenoma of the pancreas 10.4 CHGA SST SYP
36 pituitary adenoma 1, multiple types 10.4 IGF1 SST
37 binswanger's disease 10.4 CHGA SST SYP
38 lymphocytic colitis 10.4 CHGA PYY
39 pancreatic cystadenocarcinoma 10.4 CALCA CHGA SYP
40 epispadias 10.4 CALCA NPY
41 gastrinoma 10.4 CHGA MEN1 SST
42 tanycytic ependymoma 10.4 CHGA MEN1 SYP
43 pulmonary blastoma 10.4 CHGA SYP
44 ectopic cushing syndrome 10.4 MEN1 SST SYP
45 phaeochromocytoma 10.4 CHGA NPY SST
46 insulinoma 10.3 CHGA MEN1 SST
47 parathyroid adenoma 10.3 CALCA CHGA MEN1
48 pleomorphic xanthoastrocytoma 10.3 CHGA SYP
49 osteoporosis, juvenile 10.3 CALCA IGF1
50 sella turcica neoplasm 10.3 GHRH SYP

Graphical network of the top 20 diseases related to Carcinoid Syndrome:



Diseases related to Carcinoid Syndrome

Symptoms & Phenotypes for Carcinoid Syndrome

Human phenotypes related to Carcinoid Syndrome:

31 (show all 25)
# Description HPO Frequency HPO Source Accession
1 right ventricular failure 31 occasional (7.5%) HP:0001708
2 palpitations 31 occasional (7.5%) HP:0001962
3 nausea and vomiting 31 occasional (7.5%) HP:0002017
4 asthma 31 occasional (7.5%) HP:0002099
5 episodic abdominal pain 31 frequent (33%) HP:0002574
6 hepatic necrosis 31 very rare (1%) HP:0002605
7 paraganglioma 31 very rare (1%) HP:0002668
8 chronic noninfectious lymphadenopathy 31 occasional (7.5%) HP:0002730
9 elevated hepatic transaminases 31 occasional (7.5%) HP:0002910
10 increased serum serotonin 31 occasional (7.5%) HP:0003144
11 myopathy 31 very rare (1%) HP:0003198
12 protracted diarrhea 31 frequent (33%) HP:0004385
13 tricuspid regurgitation 31 occasional (7.5%) HP:0005180
14 small intestine carcinoid 31 frequent (33%) HP:0006722
15 intestinal carcinoid 31 frequent (33%) HP:0006723
16 facial telangiectasia 31 occasional (7.5%) HP:0007380
17 epiphora 31 occasional (7.5%) HP:0009926
18 bronchospasm 31 occasional (7.5%) HP:0025428
19 erythematous plaque 31 frequent (33%) HP:0025474
20 lack of bowel sounds 31 very rare (1%) HP:0030145
21 heart murmur 31 occasional (7.5%) HP:0030148
22 night sweats 31 frequent (33%) HP:0030166
23 atypical pulmonary carcinoid tumor 31 very rare (1%) HP:0030446
24 abnormal b-type natriuretic peptide level 31 occasional (7.5%) HP:0031138
25 rhinorrhea 31 occasional (7.5%) HP:0031417

MGI Mouse Phenotypes related to Carcinoid Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.9 NTS PYY SST CHGA VEGFA ENO2
2 homeostasis/metabolism MP:0005376 9.65 NTS PYY SST CHGA VEGFA GHRH
3 nervous system MP:0003631 9.36 PYY SST SYP VEGFA ENO2 GHRH

Drugs & Therapeutics for Carcinoid Syndrome

Drugs for Carcinoid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
2
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
3
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
5
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 6400441 383414
6 lanreotide Approved Phase 4,Phase 3,Phase 2,Early Phase 1 108736-35-2
7
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
8 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2
12 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
13 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2
14 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Angiopeptin Phase 4,Phase 3,Phase 2,Early Phase 1
17 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Cathartics Phase 4
19 Laxatives Phase 4
20 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21
Tranexamic Acid Approved Phase 3 1197-18-8 5526
22
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
23
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
24
Somatostatin Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
25
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
26
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
27
Ondansetron Approved Phase 3 99614-02-5 4595
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
29
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
31 interferons Phase 3,Phase 2,Phase 1
32
protease inhibitors Phase 3,Phase 2
33 3-Iodobenzylguanidine Phase 3,Phase 1
34 Coagulants Phase 3
35 Hemostatics Phase 3
36 HIV Protease Inhibitors Phase 3,Phase 2
37 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Angiogenesis Inhibitors Phase 2, Phase 3, Phase 1
39 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Angiogenesis Modulating Agents Phase 2, Phase 3, Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Antifibrinolytic Agents Phase 3
43 Antimetabolites Phase 2, Phase 3,Phase 1
44 Interferon-alpha Phase 3,Phase 2
45 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
46 Radiopharmaceuticals Phase 3,Phase 1,Phase 2,Not Applicable
47 Antiviral Agents Phase 3,Phase 2
48 Dexamethasone acetate Phase 3 1177-87-3
49
Serotonin Phase 3,Phase 2 50-67-9 5202
50 Analgesics Phase 3

Interventional clinical trials:

(show top 50) (show all 193)

# Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
3 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
4 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Recruiting NCT01789281 Phase 4 Everolimus;Sandostatin LAR Depot
5 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
6 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3 tranexamic acid;tranexamic acid
7 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
8 An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
9 Telotristat Etiprate for Carcinoid Syndrome Therapy Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
10 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
11 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
12 Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease Completed NCT00690430 Phase 3 Pasireotide;Octreotide
13 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
16 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
17 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Active, not recruiting NCT02026063 Phase 3 Telotristat etiprate tablets (250 mg)
18 A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Active, not recruiting NCT01578239 Phase 3 Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate
19 Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Active, not recruiting NCT00569127 Phase 3 Octreotide Acetate
20 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Not yet recruiting NCT03375320 Phase 3 Cabozantinib S-malate
21 Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
22 Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Terminated NCT00227136 Phase 3 5-Hydroxy-Tryptamine
23 Randomized Phase III of PRRT Versus Interferon Withdrawn NCT01860742 Phase 3 Interferon alpha-2b;177Lu-DOTATATE
24 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
25 Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
26 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
27 Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
28 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
29 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Low Dose LX1606 - Day 1 (start);Mid-low dose LX1606 - Day 15 (start);Mid-high dose LX1606 - Day 29 (start);High dose LX1606 - Day 43 (start);4-Week LX1606 Open Label Dose Extension;72-Week LX1606 Open Label Dose Extension
30 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Completed NCT00853047 Phase 2 Low Dose LX1606 Part 1;Mid-Low Dose LX1606 Part 1;Mid-High Dose LX1606 Part 1;High Dose LX1606 Part 1;Part 2 LX1606 Expanded Cohort;Placebo;LX1606 Open Label Dose Extension;LX1606 Open Label Extension 2;LX1606 Open Label Extension 3
31 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
32 Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Completed NCT02299089 Phase 2 octreotide FluidCrystal® injection depot
33 Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Completed NCT00002470 Phase 2 fluorouracil
34 Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
35 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
36 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
37 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
38 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
39 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
40 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
41 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
42 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
43 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
44 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
45 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
46 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
47 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
48 A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors Completed NCT00328497 Phase 2 Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
49 EPO906 in Carcinoid and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
50 RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Completed NCT01152827 Phase 2 RAD001

Search NIH Clinical Center for Carcinoid Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Carcinoid Syndrome

Genetic tests related to Carcinoid Syndrome:

# Genetic test Affiliating Genes
1 Carcinoid Tumor 28

Anatomical Context for Carcinoid Syndrome

MalaCards organs/tissues related to Carcinoid Syndrome:

38
Lung, Liver, Heart, Skin, Bone, Breast, Testes

Publications for Carcinoid Syndrome

Articles related to Carcinoid Syndrome:

(show top 50) (show all 549)
# Title Authors Year
1
The management of refractory carcinoid syndrome: challenges and opportunities ahead. ( 29039712 )
2018
2
Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. ( 28959913 )
2018
3
Carcinoid-syndrome: recent advances, current status and controversies. ( 29120923 )
2018
4
Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension. ( 29232344 )
2018
5
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. ( 29330194 )
2018
6
Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. ( 29350062 )
2018
7
Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report. ( 29040196 )
2017
8
Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review. ( 28454406 )
2017
9
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. ( 28642335 )
2017
10
Telotristat ethyl (Xermelo) for carcinoid syndrome diarrhea. ( 28699933 )
2017
11
Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors. ( 29142475 )
2017
12
Carcinoid Syndrome ( 28846309 )
2017
13
Lower-Extremity Vasospasm Caused by Carcinoid Syndrome. ( 29109490 )
2017
14
Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. ( 29074312 )
2017
15
Anesthetic Management of Patients With Carcinoid Syndrome and Carcinoid Heart Disease: The Mount Sinai Algorithm. ( 29273478 )
2017
16
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. ( 28238592 )
2017
17
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. ( 27918724 )
2017
18
Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply. ( 28593855 )
2017
19
Metastatic Recurrence of Typical Pulmonary Carcinoid Accompanied by Carcinoid Syndrome, Successfully Treated with Octreotide LAR. ( 29445555 )
2017
20
Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome. ( 28267211 )
2017
21
Advances in the management of patients with carcinoid syndrome. ( 28591101 )
2017
22
Carcinoid syndrome in neuroendocrine tumors: a prognostic effect? ( 28238598 )
2017
23
Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective. ( 29175096 )
2017
24
Carcinoid Syndrome and Carcinoid Heart Disease as Manifestations of Non-Metastatic Ovarian Neuroendocrine Tumour. ( 28865508 )
2017
25
Refractory carcinoid syndrome: a review of treatment options. ( 28203303 )
2017
26
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. ( 28444114 )
2017
27
Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? ( 28593854 )
2017
28
Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. ( 28562131 )
2017
29
Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea. ( 29051994 )
2017
30
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. ( 27214300 )
2016
31
Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. ( 26877616 )
2016
32
Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. ( 26917486 )
2016
33
Coronary artery spasm secondary to carcinoid syndrome. ( 27016533 )
2016
34
Complications from carcinoid syndrome: review of the current evidence. ( 27594907 )
2016
35
May depressed and anxious patients with carcinoid syndrome benefit from treatment with selective serotonin reuptake inhibitors (SSRIs)?: findings from a case report. ( 27169982 )
2016
36
The Great Deceiver: A Case of Central Sensitization Presenting as Carcinoid Syndrome. ( 27144900 )
2016
37
Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea. ( 27519265 )
2016
38
Emerging treatment options for carcinoid syndrome. ( 27673284 )
2016
39
Carcinoid Syndrome-Induced Ventricular Tachycardia. ( 27088017 )
2016
40
Endobronchial Carcinoid and Concurrent Carcinoid Syndrome in an Adolescent Female. ( 27895950 )
2016
41
Telotristat ethyl: a new option for the management of carcinoid syndrome. ( 27817224 )
2016
42
Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach. ( 27041406 )
2016
43
Carcinoid syndrome produced by an isolated metastase in femoral nerve from a midgut carcinoid tumor. ( 27026088 )
2016
44
Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. ( 25636046 )
2015
45
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. ( 26600780 )
2015
46
First-in-Human Transcatheter Pulmonic Valve Implantation Through a Tricuspid Valve Bioprosthesis to Treat Native Pulmonary Valve Regurgitation Caused by Carcinoid Syndrome. ( 26315750 )
2015
47
Primary neuroendocrine mediastinal tumor presenting with carcinoid syndrome and left supraclavicular lymphadenopathy. Clinico-radiological and pathological features. ( 26881686 )
2015
48
Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): subgroup analysis of the ELECT study. ( 26431405 )
2015
49
Primary Metastatic Small Intestinal Carcinoid Tumor Without Carcinoid Syndrome. ( 26470900 )
2015
50
Intractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization. ( 26188238 )
2015

Variations for Carcinoid Syndrome

Expression for Carcinoid Syndrome

Search GEO for disease gene expression data for Carcinoid Syndrome.

Pathways for Carcinoid Syndrome

Pathways related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.99 CALCA ENO2 NPY SYP
2 11.13 ENO2 IGF1 VEGFA
3 10.7 IGF1 SYP VEGFA
4 10.62 NPY PYY

GO Terms for Carcinoid Syndrome

Cellular components related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CALCA CHGA GHRH IFNA2 IGF1 NPY
2 neuronal cell body GO:0043025 9.56 CALCA ENO2 HTR3A SST
3 terminal bouton GO:0043195 9.33 CALCA GHRH SYP
4 extracellular space GO:0005615 9.32 CALCA CHGA ENO2 GHRH IFNA2 IGF1

Biological processes related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.69 CALCA NPY PYY
2 movement of cell or subcellular component GO:0006928 9.61 IGF1 NPY PYY
3 regulation of blood pressure GO:0008217 9.58 CALCA CHGA NPY
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 IFNA2 IGF1 VEGFA
5 digestion GO:0007586 9.5 NPY PYY SST
6 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.49 GHRH IGF1
7 positive regulation of cAMP metabolic process GO:0030816 9.48 CALCA CHGA
8 regulation of appetite GO:0032098 9.46 NPY PYY
9 response to heat GO:0009408 9.43 CALCA IGF1 SST
10 cell-cell signaling GO:0007267 9.35 CALCA GHRH IFNA2 PYY SST
11 feeding behavior GO:0007631 9.33 CALCA NPY PYY
12 regulation of receptor activity GO:0010469 9.28 CALCA GHRH IFNA2 IGF1 NPY NTS
13 G-protein coupled receptor signaling pathway GO:0007186 10 CALCA GHRH NPY NTS PYY SST

Molecular functions related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.13 NPY NTS PYY
2 hormone activity GO:0005179 9.02 CALCA IGF1 NPY PYY SST

Sources for Carcinoid Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....